PHARMACIE LEFEBURE
ActiveSummary
PHARMACIE LEFEBURE has been active since 1978 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €913,709 and a net result of €107,372. Equity has been stable since 2018 (±1.8% per year). Its solvency ranks better than 68% of 12,781 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Overview
Official details
Source: KBO- Status
- Active since 27-06-1978 Normal situation
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Joint committee
- 313 Paritair Comité voor de apotheken en tarificatiediensten · annual accounts 2025
- Establishment unit
- 2.015.033.557 7500 Tournai, since 01-08-1978
- Financial year end
- 31 December
- Peppol
- Reachable since 24-10-2025
Board and ownership
- ML INVESTDirector · since 08-12-2023 · permanent representative Marc Lefebure
Financial position
- Bankruptcy probabilitywithin 12 months
- < 0.1%
- Gross margin
- €718,292
- ▲ 8.1%
- Turnover
- ≈ €2.6m
- estimated
- Profit
- €107,372
- ▼ 33.1%
- Equity
- €913,709
- ▲ 13.3%
- Total assets
- €1.7m
- ▼ 21.4%
- Employees on 31-12-2025
- 9
- ▲ 12.5%
Score breakdownlowers riskLiquidity: current ratio 2.51, cash €556,654Founded in 1978Equity €913,709 (54.9% of total assets)Profit of €107,372 (financial year 2025)Show the evidence
Checked score
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 68% of them on solvency, 84% on liquidity, 65% on profitability and 65% on growth.
The bankruptcy probability was computed on 04-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
The company filed its last 7 accounts on average 25 days before the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
Key points
- Positive: More equity than 85% of companies in retail tradesector median €236,595 · 12,791 companies €913,709 View
- Positive: 8 profitable years in a rowprofit 2025: €107,372 8 years View
- Caution: Result fell in 2025from €160,404 to €107,372 ▼ 33.1% View
- Positive: Filed on time since financial year 2022accounts within the deadline every year 4 years View
Recent changes
- · Gazette deed Change of role: ML Invest, from manager to directorPermanent representative: Marc Lefebure · ML Invest holds all the shares
Comparable companies
These companies have the same main activity as PHARMACIE LEFEBURE: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.6m and €1.8m, founded between 1978 and 1993.
| Company | Total assets | Gross margin |
|---|---|---|
| PHARMACIE LEFEBURE Tournai | €1.7m | €0.7m |
| LUDAPHAR Beauvechain | €1.8m | €0.6m |
| Jeandarme Sint-Truiden | €1.6m | €0.8m |
| Pharmacie Bastin Médiacité Liège | €1.8m | €0.8m |
| PHARMACIE LUC MOREL Mouscron | €1.8m | €0.6m |
| Apotheek Sollie Antwerpen | €1.8m | €1.0m |
| PHARGEST Profondeville | €1.8m | €0.7m |
Key facts about PHARMACIE LEFEBURE
- What is the company number of PHARMACIE LEFEBURE?
- The company number of PHARMACIE LEFEBURE is 0418.438.697. The VAT number is the same number with BE in front: BE 0418.438.697.
- Where is PHARMACIE LEFEBURE based?
- The registered office is at Boulevard Eisenhower(TOU) 25, 7500 Tournai.Company details
- What does PHARMACIE LEFEBURE do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMACIE LEFEBURE?
- The legal form of PHARMACIE LEFEBURE is Private limited company (BV).
- When was PHARMACIE LEFEBURE founded?
- PHARMACIE LEFEBURE was founded on 27-06-1978.
- Is PHARMACIE LEFEBURE still active?
- Yes, PHARMACIE LEFEBURE is an active enterprise in the KBO register.
- How many employees does PHARMACIE LEFEBURE have?
- PHARMACIE LEFEBURE had an average of 7.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- Which joint committee does PHARMACIE LEFEBURE fall under?
- In its 2025 annual accounts, PHARMACIE LEFEBURE states joint committee 313 (Paritair Comité voor de apotheken en tarificatiediensten).
- What is the turnover of PHARMACIE LEFEBURE?
- The turnover in financial year 2025 is ≈ €2.6m. This figure is estimated from the gross margin of €718,292 and 47 comparable companies (NACE 477). It probably lies between €2.0m and €4.3m.
- Is PHARMACIE LEFEBURE profitable?
- In financial year 2025, PHARMACIE LEFEBURE made a profit of €107,372.
- Where can I find the annual accounts of PHARMACIE LEFEBURE?
- PHARMACIE LEFEBURE filed 48 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMACIE LEFEBURE due?
- PHARMACIE LEFEBURE must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
See how customers, suppliers and banks see your own company and what to improve first.